References

1. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, et al. (2015) Feasability of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J ClinOncol 33: 2753-2762. View
2. Zehir A, Benayed R, Shah RH, Syed A, Middha S, et al. (2017) Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23: 703-713. View
3. Prasad V (2016) Perspective: The precision-oncology illusion. Nature 537: S63. View
4. Abrahams E, Eck S (2016) Molecular medicine: Precision oncology is not an illusion. Nature 539: 357. View
5. Schram AM, Berger MF and Hyman DM (2017) Precision oncology: Charting a path forward to broader deployment of genomic profiling. PLoS Med 14: e1002242. View
6. Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R, et al. (2017) Do patient access schemes for high-cost cancer drugs deliver value to society? – Lessons from the NHS Cancer Drugs Fund. Ann Oncol Ann Oncol 28:1738-1750. View
7. Turck R (2017) Oncology drug costs – the imaginary crisis? Ann Oncol 28: 427-431. View
8. Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, et al. ((2010) Pilot study using molecular profiling of patients' tumours to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28: 4877-4883. View
9. Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, et al. (2014) A Pilot Study Utilizing Multi-omic Molecular Profiling to find Potential Targets and Select Individualized Treatments for Patients with Previously Treated Metastatic Breast Cancer. Breast Cancer Res Treat 147: 579-588. View
10. Dean A, Wallace R (2016) Clinical outcomes of patients with rare and heavily pretreated solid tumors treated according to the results of tumor molecular profiling. BioMed Res Int 2016: 4627214. View
11. Popovtzer A, Sarfaty M, Limon D, Marshack G, Perlow E, et al. ( 2015) Metastatic Salivary Gland Tumours: A Single-center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-profiling-guided Therapy. BioMed Res Int 2015: 614845. View
12. Barrett MT, Lenkiewicz E, Evers L, Holley T, Aziz M, Kiefer J, et al. (2012) Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001. Cancer Res 72: Abstract nr 3697. View
13. Epelbaum R, Shacham-Shmueli E, Klein B, Agbarya A, Brenner B, et al. (2015) Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. BioMed Res Int 2015: 681653. View
14. Purim O, Beny A, Inbar MJ, Brenner B, Dudnik E, et al. (2017) Molecular profiling-selected treatment in metastatic gastric and esophageal cancer: Real-life clinical experience. Journal of Clinical Oncology 35: e15537. View
15. Seeber A, Gastl G, Ensinger C et al. Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. Genes Cancer 7: 301-310. View
16. Ahmadie A, El KarakF, Farhat F, Kattan J, Hanna C, et al. (2015) Molecular Profiling guided treatment in refractory solid tumours: practical impact and clinical responses: Experience of a single center. European Journal of Cancer 51: S43. View
17. Chahine G, Nasr F, Saleh K (2016) Clinical outcomes of patients with previously treated advanced or metastatic cancer before or after tumour profiling: results of a monocentric pilot study in Lebanon, ICACT.
18. El Nahas T (2017) Multiplatform molecular profiling to determine treatment selection in rare, aggressive, refractory and metastatic cancers with limited treatment options, ICACT.
19. Ferreira AR, Gomes ASDA, Costa FP (2014) Next generation sequencing – A key in search of locks? Ann Oncol 25: iv560. View
20. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, et al. (2014) Triplenegative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: Improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther 13: 3175-3184. View
21. Brandao Moreira R, Peixoto R, de Sousa TTS, Cruz M, Maluf F, et al. (2015) Next-generation sequencing (NGS) in metastatic breast cancer (mBC) patients: Translation from sequence data into clinical practice. J Clin Oncol 33: 133-133. View
22. Brandao Moreira R, Alessandretti MB, Abrahao CM, et al. (2015) Nextgeneration sequencing (NGS) in metastatic gastrointestinal cancer (mGIC) patients: Translation from sequence data into clinical practice. J Clin Oncol 33: 133-133. View
23. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, et al. (2016) Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res 76: 3690-3701. View
24. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, et al. (2016) Precision oncology: the UC San Diego Moores Cancer Center PREDICT experience. Mol Cancer Ther 15: 743-752. View
25. Sohal DP, Rini BI, Khorana AA, Dreicer R, Abraham J, et al. (2016) Prospective clinical study of precision oncology in solid tumours. J Natl Cancer Inst 108: pii-djv332. View
26. Blumenthal DT, Dvir A, Lossos A, Tzuk-Shina T, Lior T, et al. Clinical utility and treatment outcome of comprehensive genomic profiling in high gradeglioma patients. J Neurooncol 130: 211-219. View
27. Rodriguez-Rodriguez L, Hirshfield KM, Rojas V, DiPaola RS, Gibbon D, et al. (2016) Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. Gynecol Oncol 141: 2-9. View
28. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, et al. (2014) Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 19: 616- 622. View
29. Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, et al. Clinical actionability of comprehensive profiling for management of rare or refractory cancers. Oncologist 21: 1315-1325. View
30. Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, et al. (2017) Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 8: 39254-39267. View
31. Koenig KL, Burkart J, Mikhail S, Wu CSY, Noonan Am, et al. (2016) Therapeutic impact and timing of gastrointestinal malignancy genomic profiling: A single-institution experience. J Clin Oncol 34: 584-584. View
32. Dhir M, Choudry HA, Holtman MP, Pingpank JF, Ahrendt SA, et al. (2017) Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies. Cancer Med 6: 195-206. View
33. Yuan Y, Yost SE, Yuan YC, Solomon NM, Mambetsariev I (2017) genomic mutation-driven metastatic breast cancer therapy: a single center experience. Oncotarget 8: 26414-26423. View
34. Grenader T, Tauber R, Shavit L (2016) Next-generation-sequencing in patients with advanced cancer: are we ready for widespread clinical use? A single institute’s experience. Anticancer Drugs 27: 899-907. View
35. Gunderson CC, Rowland MR, Wright DL, Andrade KL, et al. (2016) Initiation of a formalized precision medicine program in gynecological oncology. GynecolOncol 141: 24-28. View
36. Groisberg R, Hong DS, Janku F, Groisberg R, Hong DS, Janku F, et al. (2017) Clinical next generation sequencing for precision medicine in rare cancers. J Clin Oncol 35: 2582-2582. View
37. Dalton WB, Forde PM, Kang H, Connolly Rm, Stearns V, et al. (2017) Personalized medicine in the oncology clinic: Implementation and outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precision Oncology 1: 1-19. View
38. Hodeib M, Prendergast EN, Liu AY, Fahey JN, Elvin JA, et al. (2017) Comprehensive genomic profiling of rare gynecological malignancies. Gynecologic Oncology 145: 212. View
39. Sicklick JK, Leyland-Jones B, Kato S, Hahn M, Williams C, et al. (2017) Personalized, molecularly matched combination therapies for treatmentna. J Clin Oncol 35: 2512-2512. View
40. Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, et al. (2017) Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget 8: 27145-27154. View
41. Braiteh F, Sharman JP, Richards DA, Skelton MR, DeMarco C, et al. (2014) Clinical NGS-based cancer genomic profiling impacts physician treatment decisions in advanced solid tumours. J Clin Oncol 32: 11109-11109. View
42. DiBardino DM, Saqi A, Elvin JA, Greenbowe J, Suh JH, et al. (2016) Yield and clinical utility of next-generation sequencing in selected patients with lung adenocarcinoma. Clin Lung Cancer 17: 517-522. View
43. Mantripragada KC, Olszewski AJ, Schumacher A, Perez K, Birnbaum A, et al. (2016) Clinical Trial Accrual Targeting Genomic Alterations after Next- Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program. J Oncol Pract 12: e396-e404. View
44. Reinbolt RE, Tolliver K, Abdel-Rasoul M, Timmers CD, Ramaswamy B, et al. (2016) Decision impact analysis of comprehensive genomic profiling (CGP) in advanced breast cancer: A prospective study. J Clin Oncol 34: 11578-11578. View
45. Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, et al. (2016) Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget 7: 56491-56500. View
46. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, et al. (2012) Personalized medicine in a phase I clinical trials program: the MD Anderon Cancer Center initiative. Clin Cancer Res18: 6373-6383. View
47. Stockley TL, Oza AM, Berman HK Leighl NB, Knox JJ, et al. (2016) Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: The Princess Margaret IMPACT/ COMPACT trial. Genome Med 8: 109. View
48. Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, et al. (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicenter, openlabel, proof-of-concept, randomized, controlled phase 2 trial. Lancet Oncology 16: 1324-1334. View
49. Massard C (2015) Enriching phase I trials with molecular alterations: Interim analysis of 708 patients enrolled in the MOSCATO 01. Ann Oncol 26: ii4. View
50. Andrè F, Bachelot T, Commo F, Campone M, Arnedos M, et al. (2014) Comparative genomic hybridization array and DNA sequencing to direct treatment of metastatic breast cancer: a multicenter, prospective trial (SAFIR01/UNICANCER). The Lancet Oncology 15: 267-274. View
51. Cousin S, Grellety T, Toulmonde M, Auzanneau C, Khalifa E, et al. (2017) Clinical impact of extensive molecular profiling in advanced cancer patients. J HematolOncol 10: 45. View
52. Dienstmann R1, Serpico D, Rodon J, Saura C, Macarulla T, et al. (2012) Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther 11: 2062-2071. View
53. Kim ST, Lee J, Hong M, Park K, Park JO, et al. (2015) The NEXT-1 (Next generation pErsonlizedtX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. Oncotarget 6: 33358-33368. View
54. Tanabe Y, Ichikawa H, Kohno T, Yoshida H, Kubo T, et al. (2016) Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. Mol Cancer 15: 73. View
55. Ramírez de Olano A, Bellmunt J, Rodrigo A, Álvarez L, Terrádez A, et al. (2017) A case report demonstrating the potential clinical benefit of exhaustive molecular profiling in an aggressive muscle-invasive high-grade metastatic urothelial carcinoma. Case Rep Oncol 10: 493-500. View
56. Smart A (2006) A multi-dimensional model of clinical utility. Int J Qual Health Care 18: 377-382. View
57. Peabody JW, Shimkhada R, Tong KB, Zubiller MB (2014) New thinking on clinical utility: Hard lessons for molecular diagnostics. Am J Manag Care 20: 750-756. View
58. Borrebaeck CAK (2017) Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nat Rev Cancer 17: 199- 204. View
59. Batty GD, Russ TC, Stamatakis E, Kivimäki M, et al. (2017) Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies. BMJ 356: j108. View
60. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, et al. (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31: 1023- 1031. View
61. Deans ZC, Costa JL, Cree I, Dequeker E, Edsjö A, et al. (2017) Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf og IQN Path ASBL. Virchows Arch 470: 5-20. View
62. Salipante SJ, Kawashima T, Rosenthal C, Hoogestraat DR, Cummings LA, et al. (2014) Performance Comparison of Illumina and Ion Torrent Next-Generation Sequencing Platforms for 16S rRNA-Based Bacterial Community Profiling. Appl Environ Microbiol 80: 7583-7591. View
63. Weiss GJ, Hoff BR, Whitehead RP, Sangal A, Penny RJ, et al. (2015) Evaluation and comparison of two commercially available targeted nextgeneration sequencing platforms to assist oncology decision making. Onco Targets Ther 8: 959-967. View
64. Simon A, Kourie HR, Kerger J (2017) Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review. Chin J Cancer 36: 10. View
65. Schrock AB, Frampton GM, Herndon D, Greenbowe JR, Wang K, et al. (2016) Comprehensive Genomic Profiling Identifies Frequent Drug Sensitive EGFR Exon 19 Deletions in NSCLC Not Identified by Prior Molecular Testing. Clin Cancer Res 22: 3281-3285. View
66. O'Hurley G, Sjöstedt E, Rahman A, Li B, Kampf C, et al. (2014) Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol Oncol 8: 783-798. View
67. David KA, Juhl H (2015) Immunohistochemical Detection of Phosphoproteins and Cancer Pathways. In: Lin F., Prichard J. (eds) Handbook of Practical Immunohistochemistry. Springer, New York, NY. View
68. Shen C, Meric-Bernstam F, Su X et al. (2016) Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel. Oncotarget 7: 71686-71695. View
69. https://assets.contentful.com/vhribv12lmne/5BJHWaCe1Gwu8CaksomG S8/653f19c8657097e43fad4aabbc6495a4/Patient_Information_Guide_5. pdf View
70. h t t p : / / w w w. p a r a d i g m d x . c o m / w p - c o n t e n t / u p l o a d s / 2 0 1 4 / 0 8 / ParadigmPCDxFAQs4-2014.pdf View
71. http://data.consilium.europa.eu/doc/document/PE-15-2017-INIT/en/pdf View